1. Introduction {#s0005}
===============

*Acinetobacter baumannii*, an aerobic Gram-negative coccobacillus, is an opportunistic pathogen, especially to immunocompromised patients hospitalized in intensive care units (ICUs) ([@b0010]). In recent decades, *A. baumannii* has emerged as a common nosocomial pathogen causing severe infections including septicemia, pneumonia, meningitis, urinary tract infections, and infections stemming from wounds ([@b0010], [@b0085], [@b0145]). Presence of risk factors such as exposure to antimicrobial agents, colonization pressure, or acquisition of genetic elements carrying antibiotic-resistance genes, increase the emerging of multidrug-resistant *A. baumannii* (MDRAB) and has posed a great therapeutic challenge for clinicians ([@b0145], [@b0175]). Alternative therapies such as antimicrobial combination therapy or new antimicrobial agents from natural resources, *e.g.*, insect ([@b0075]), amphibian ([@b0170]), and mammalian ([@b0110]), have been demonstrated as potential options for combating this microorganism.

Recently, [@b0190] reported that antimicrobial peptides from natural resources, particularly mastoparan, effectively restraint the growth of colistin-resistant *A. baumannii*. Mastoparans (MPs), the most abundant peptide from *Vespidae* venoms ([@b0165]), consist of 14 amino acid residues including several hydrophobic amino acids such as leucine, isoleucine, valine or alanine, 2--4 lysine residues, and an amidated C-terminal residue ([@b0125], [@b0155]). MPs could form amphipathic helical structures under an appropriate environment, *e.g.*, aqueous trifluoroethanol solution ([@b0030], [@b0125], [@b0205]). MPs exhibit a variety of biological activities, including mast cell degranulation and release of histamine ([@b0025], [@b0125]), hemolytic activity ([@b0025], [@b0125]), and activation of phospholipase A~2~ and phospholipase C ([@b0185]). Furthermore, MPs show broad-spectrum antimicrobial activity against both Gram-positive and -negative bacteria ([@b0025], [@b0080], [@b0115], [@b0125]), and cause membrane permeabilization on *Escherichia coli* BL21 ([@b0125]).

In our previous study, Mastoparan-AF (MP-AF), isolated from the hornet venom of *Vespa affinis*, presented potent antimicrobial activity, especially against multidrug-resistant *E. coli* isolates from animals ([@b0130]). More importantly, MP-AF displayed ignorable human erythrocyte hemolysis at 32 μg/ml that over the effective antimicrobial concentration to *Citrobacter koseri*, *E. coli*, *Salmonella enterica* Serotype Choleraesuis, and *Vibrio parahaemolyticus* ([@b0125]). In addition, MP-AF also in combination with cephalothin or gentamicin displayed a synergistic activity against *E. coli* clinical isolates ([@b0130]). Therefore, use of MP-AF along with antibiotics harboring different mechanisms of action, could be a feasible strategy to combat MDRAB.

The purpose of this study was to investigate the *in vitro* activity of MP-AF alone or in combination with eight clinically used antibiotics against MDR nosocomial isolates of *A. baumannii* and to evaluate whether this strategy could be as novel therapeutic options for MDRAB infections.

2. Materials and methods {#s0010}
========================

2.1. Bacterial isolates {#s0015}
-----------------------

Seven *A. baumannii* clinical strains were isolated from patients' blood and urine in Laboratory Medicine, Department of Health, Executive Yuan, Fong-Yuan Hospital, Taiwan. In addition, *A. baumannii* ATCC 15151, a reference strain from Bioresource Collection and Research Center (BCRC), Taiwan, was used as a control. Identification of all clinical isolates were further confirmed by PCR and DNA sequencing using bacterium-specific universal primers, 1512F (5′-GTCGTAACAAGGTAGCCGTA-3′) and 6R (5′-GGGTTYCCCCRTTCRGAAAT-3′, where Y is C or T and R is A or G) ([@b0020]).

2.2. Genetic analysis of RND efflux pump, OXA-carbapenemase, class 1 integron genes and IS elements {#s0020}
---------------------------------------------------------------------------------------------------

Detection of resistance-nodulation-cell division (RND) efflux pump genes (*adeA*, *adeB*, *adeC*, *adeI*, *adeJ*, *adeR* and *adeS*) was performed by PCR using specific primers. The OXA-carbapenemase genes encoding carbapenem-hydrolysing β-lactamases (*bla*~OXA-23-like~, *bla*~OXA-51-like~ and *bla*~OXA-58-like~) were analyzed using PCR. In addition, class 1 integron gene (integrase gene *int1*) and IS elements (IS*Aba1*, IS*Aba2* and IS*Aba3*) were also examined by PCR. Sequences of primers used for detecting of antibiotic resistance genes and PCR conditions were shown in [Table 1](#t0005){ref-type="table"}.Table 1Primers for amplify of antibiotic resistant genes and annealing temperatures used in this study.Target geneForward primer sequences (5′ → 3′)Reverse primer sequences (5′ → 3′)Amplicon size (bp)Annealing temp (°C)References*adeA*adeA-F: ATCTTCCTGCACGTGTACATadeA-R: GGCGTTCATACTCACTAACC51350[@b0120]*adeB*adeB-F: TTAACGATAGCGTTGTAACCadeB-R: TGAGCAGACAATGGAATAGT54150[@b0120]*adeC*adeC-F: AGCCTGCAATTACATCTCATadeC-R: TGGCACTTCACTATCAATAC56050[@b0120]*adeI*adeI-F: ATCGCGCTTGTTGGTTGTAGadeI-R: AAGCACCAGCCGTTACTGAA54150[@b0120]*adeJ*adeJ-F: ATTGCACCACCAACCGTAACadeJ-R: TAGCTGGATCAAGCCAGATA45350[@b0120]*adeR*adeR-F: ACTACGATATTGGCGACATTadeR-R: GCGTCAGATTAAGCAAGATT44750[@b0120]*adeS*adeS-F: TTGGTTAGCCACTGTTATCTadeS-R: AGTGGACGTTAGGTCAAGTT54450[@b0120]*int1*Int1F: CAGTGGACATAAGCCTGTTCInt1R: CCCGAGGCATAGACTGTA16050[@b0090]*bla*~OXA23~OXA-23-like-F: GATCGGATTGGAGAACCAGAOXA-23-like-R: ATTTCTGACCGCATTTCCAT50150[@b0200]*bla*~OXA51~OXA-51-like-F: TAATGCTTTGATCGGCCTTGOXA-51-like-R: TGGATTGCACTTCATCTTGG35350[@b0200]*bla*~OXA58~OXA-58-like-F: AAGTATTGGGGCTTGTGCTGOXA-58-like-R: CCCCTCTGCGCTCTACATAC59950[@b0200]IS*Aba1*ISAbla1A: GTGCTTTGCGCTCATCATGCISAbla1B: CATGTAAACCAATGCTCACC40050[@b0180]IS*Aba2*ISAbla2A: AATCCGAGATAGAGCGGTTCISAbla2B: TGACACATAACCTAGTGCAC1,30652[@b0180]IS*Aba3*ISAbla3A: CAATCAAATGTCCAACCTGCISAbla3B: CGTTTACCCCAAACATAAGC37452[@b0180]

2.3. Antimicrobial agents {#s0025}
-------------------------

Mastoparan-AF (MP-AF), INLKAIAALAKKLF-NH~2~, was synthesized and purified by Bio Basic Inc. (Ontario, Canada). The crude synthetic MP-AF was further purified by reverse phase HPLC equipped with Sino Chrom ODS-BP (4.6 × 250 mm, 5 μm) under a linear gradient from 35% to 60% (v/v) acetonitrile in water containing 0.1% trifluoroacetic acid, at a flow rate of 1.0 ml/min during 30 min by monitoring at 220 nm. The purity of synthetic MP-AF was over 95%. The molecular weight of the synthetic MP-AF was subsequently confirmed by an electrospray ionization mass spectrometry (ESI-MS). The MP-AF stock solution (10 mg/ml) was prepared by dissolving lyophilized powder in sterile distilled water and stored at −20 °C before use.

Antibiotics tested were purchased from the manufacturers as follows: ampicillin (GERBU, Wieblingen, Germany), cephalothin (Sigma, St. Louis, USA), ciprofloxacin (Fluka, St. Louis, USA), colistin sulfate salt (Sigma, St. Louis, USA), gentamicin (Sigma, St. Louis, USA), neomycin (Sigma, St. Louis, USA), trimethoprim/sulfamethoxazole (SXT) (Sigma, St. Louis, USA), tetracycline (GERBU, Wieblingen, Germany) and tigecycline (Glentham Life Science, Wiltshire, UK). All antibiotics stock solutions (10 mg/ml) were also prepared by dissolving lyophilized powder in distilled water, then sterilized by passing through 0.22 μm filter. All of these sterilized stock solutions were stored at −20 °C until use.

2.4. Antimicrobial susceptibility testing {#s0030}
-----------------------------------------

The antimicrobial disk diffusion susceptibility test was performed by using amikacin (AN, 30 μg), ceftazidime (CAZ, 30 μg), ciprofloxacin (CIP, 5 μg), ceftriaxone (CRO, 30 μg), cefotaxime (CTX, 30 μg), cefepime (FEP, 30 μg), gentamicin (GM, 10 μg), imipenem (IPM, 10 μg), levofloxacin (LVX, 5 μg), minocycline (MI, 30 μg), ampicillin/sulbactam (SAM, 10/10 μg), trimethoprim/sulfamethoxazole (SXT, 1.25/23.75 μg) and piperacillin/tazobactam (TZP, 100/10 μg) disks, and the results were interpreted as "susceptible", "intermediate" or "resistant" according to the Clinical and Laboratory Standards Institute (CLSI) guidelines described in CLSI M100-S22 ([@b0035]).

Minimal inhibitory concentrations (MICs) of antimicrobial agents against *A. baumannii* isolates were determined by the broth micro-dilution method described in CLSI M07-A9 ([@b0040]) with slight modifications. Serial doubling dilutions of antimicrobial agents were made in Mueller Hinton broth (MHB) to the final volume of 100 μl in each well of a 96-well round bottom microtitre plate. Subsequently, 100 μl of bacterial suspension grown in MHB were inoculated into each well to obtain the final concentration of 5 × 10^5^ CFU/ml and then incubated at 35 °C for 24 h. After 24 h of incubation, plates were read for visual turbidity and estimated based on optical density at 620 nm in each well. The MIC is defined as the lowest concentration of antimicrobial agent that showing no visual bacterial growth (optically clear well). Experiments were performed in duplicates in three independent experiments. The MICs are presented as the median values obtained in duplicates from three independent experiments.

2.5. Synergistic antimicrobial combination studies {#s0035}
--------------------------------------------------

In combination studies, *A. baumannii* clinical isolates were used to test the antimicrobial combinations by a chequerboard titration method using 96-well round bottom microtitre plate. MP-AF was diluted by serial 2-fold steps vertically and antibiotic was also diluted in 2-fold steps horizontally. The ranges of MP-AF dilutions used were from 64 to 0.5 μg/ml, concentrations of colistin were from 32 to 0.0625 μg/ml, and those for seven antibiotics were from 256 to 0.5 μg/ml. The fractional inhibitory concentration (FIC) index for the combination of two antimicrobials was calculated from the following equation: FIC index = FIC~A~ + FIC~B~ = A/MIC~A~ + B/MIC~B~, where A and B are the MICs of drug A and drug B in the combination, MIC~A~ and MIC~B~ are median MICs of drug A and drug B alone, and FIC~A~ and FIC~B~ are FICs of drug A and drug B. The FIC indexes were interpreted as follows: FIC ⩽ 0.5, synergy; 0.5 \< FIC \< 1, partial synergy; FIC = 1, additivity; 1 \< FIC \< 4, indifference; FIC ⩾ 4.0, antagonism ([@b0050]). The FIC indexes were obtained from three independent experiments.

3. Results {#s0040}
==========

3.1. Analysis of RND efflux pump, OXA-carbapenemase, *int1* genes and IS elements in *A. baumannii* clinical isolates {#s0045}
---------------------------------------------------------------------------------------------------------------------

Genetic analysis of seven *A. baumannii* isolates, shown in [Table 2](#t0010){ref-type="table"}, revealed that all *A. baumannii* clinical isolates were PCR positive for RND efflux pump and *int1* genes. As [@b0095] described, *A. baumannii* ATCC 15151 was also positive for RND efflux pump. OXA-carbepenemase was associated with *bla*~OXA23~, *bla*~OXA51~ and *bla*~OXA58~ genes. Among these genes detected, *bla*~OXA23~ and *bla*~OXA51~ was detected in all *A. baumannii* isolates, but *bla*~OXA58~ was not detected. IS*Aba1* was detected in all *A. baumannii* isolates, but none of IS*Aba2* and IS*Aba3* was detected in tested isolates.Table 2Resistance-nodulation-cell division efflux pump genes, class 1 integron gene, OXA-carbapenemase genes and IS elements detected in *A. baumannii* clinical isolates.*A. baumannii* isolatesChromosomePlasmidResistance-nodulation-cell division (RND) efflux pump genesClass 1 integron geneOXA-carbapenemase genesIS elements*adeAadeBadeCadeIadeJadeRadeSint1bla*~OXA23~*bla*~OXA51~*bla*~OXA58~IS*Aba1*IS*Aba2*IS*Aba3*E0158++++++++++−+−−E0407++++++++++−+−−E0469++++++++++−+−−E0528++++++++++−+−−E0682++++++++++−+−−E0948++++++++++−+−−E1359++++++++++−+−−ATCC 15151+++++++−−+−−−−[^1]

The 16S-23S rRNA gene spacer region sequences of 7 MDRAB were submitted to GenBank. Accession numbers were shown as follows: E0158 (KR732279), E0407 (KR732281), E0469 (KR732282), E0528 (KR732283), E0682 (KR732284), E0948 (KR732286) and E1359 (KR732287).

3.2. *In vitro* activity of MP-AF and clinically used antibiotics against *A. baumannii* clinical isolates {#s0050}
----------------------------------------------------------------------------------------------------------

Antimicrobial susceptibility profiles of the seven *A. baumannii* clinical isolates tested by different types of antibiotics were shown in [Table 3](#t0015){ref-type="table"}. It is found that all isolates were susceptible to MI, but resistant to GM, TZP, CAZ, CTX, CRO, IMP, CIP and SXT, and most of them were resistant to AN (5/7), SAM (4/7), FEP (6/7), LVX (5/7). Interpretive criteria for tigecycline MICs were based on the United States Food and Drug Administration (FDA) criteria ([@b0005], [@b0160]), it showed that all isolates were also susceptible to tigecycline. According to MIC interpretive criteria described by [@b0035], it revealed that six isolates were susceptible to colistin except E0158. As mentioned above, all clinical isolates were resistant to at least one antimicrobial agent in three or more antimicrobial classes and could be defined as MDRAB based on definition for multi-drug resistant (MDR) bacteria described by [@b0135]. In addition, *A. baumannii* ATCC 15151 was susceptible to antibiotics tested and it also corresponds with [@b0015] described.Table 3Antimicrobial susceptibility profiles of *A. baumannii* clinical isolates in this study.*A. baumannii* isolatesYearOriginsAntimicrobial susceptibility profiles for *A. baumannii* clinical isolatesAntimicrobial classesAminoglycosideβ-Lactam/β-lactamase inhibitor combinationCephemPenemQuinoloneFolate pathway inhibitorTetracyclineANGMSAMTZPCAZCTXCROFEPIMPCIPLVXSXTMIE01582007BloodRRSRRRRIRRIRSE04072008UrineRRIRRRRRRRRRSE04692008UrineSRRRRRRRRRRRSE05282008BloodSRIRRRRRRRRRSE06822008UrineRRRRRRRRRRRRSE09482009BloodRRRRRRRRRRRRSE13592010UrineRRRRR--RRRR--RSATCC 15151SSSSSSSSSSSSS[^2][^3]

The median MICs of MP-AF and nine antibiotics tested against the reference strain, ATCC 15151, and seven MDRAB isolates are summarized in [Table 4](#t0020){ref-type="table"}. MP-AF exhibited potent antimicrobial activity against *A. baumannii* tested, at 2 μg/ml against ATCC 15151, 4 μg/ml against E0469, E0528, E0682 and E0948, 8 μg/ml against E0158 and E0407 and 16 μg/ml against E1359. Colistin showed low MICs, at 1 μg/ml for E0407, E0948, E1359 and ATCC 15151, 2 μg/ml for E0469, E0528 and E0682, and 4 μg/ml for E0158. Ampicillin, cephalothin and gentamicin could not inhibit growth of isolates at 256 μg/ml, but showed low MICs of 16, 8 and 1 μg/ml against ATCC 15151. Ciprofloxacin presented MICs of 64 and 0.5 μg/ml against E0407 and ATCC 15151, respectively, but has no effects on other bacterial growth even at the concentration of 256 μg/ml. Neomycin displayed MICs at 1 μg/ml for ATCC 15151, 256 μg/ml for E0469 and E0948, but no inhibitory effects on the rest of isolates at 256 μg/ml. SXT showed MICs at 64 μg/ml for E0682, 256 μg/ml for E0407 and 2 μg/ml for ATCC 15151, but no activity against other isolates at 256 μg/ml. Tetracycline exhibited activity against *A. baumannii* at 4 μg/ml for ATCC 15151, 128 μg/ml for E0407, E0469 and E0948, and 256 μg/ml for E0528 and E0682, but showed ineffective against E0158 and E1359 even at 256 μg/ml. Tigecycline showed the lowest MICs, at 0.0625 μg/ml for E0528, 0.125 μg/ml for E0682, E0948 and ATCC 15151, 0.25 μg/ml for E0407 and E0469 and 0.5 μg/ml for E0158 and E1359. Except colistin and tigecycline, MP-AF presented superior antimicrobial activity against *A. baumannii* clinical isolates than other antibiotics used in this study.Table 4Median minimal inhibitory concentration of MP-AF and clinical used antibiotics against *A. baumannii* clinical isolates.*A. baumannii* isolatesMedian MIC (μg/ml)MP-AFAMPCFCIPCLGMNEOSXTTETTGCE01588\>256\>256\>2564\>256\>256\>256\>2560.5E04078\>256\>256641\>256\>2562561280.25E04694\>256\>256\>2562\>256256\>2561280.25E05284\>256\>256\>2562\>256\>256\>2562560.0625E06824\>256\>256\>2562\>256\>256642560.125E09484\>256\>256\>2561\>256256\>2561280.125E135916\>256\>256\>2561\>256\>256\>256\>2560.5ATCC 1515121680.5111240.125[^4]

3.3. Evaluation of the efficacy of MP-AF combined with clinically used antibiotics against MDRAB {#s0055}
------------------------------------------------------------------------------------------------

The efficacy of MP-AF combined with clinically used antibiotics against MDRAB was estimated by FIC indexes as shown in [Table 5](#t0025){ref-type="table"}. MP-AF combined with colistin presented synergistic activity against E0158, E0407, E0469, E0528, E0948 and E1359, showing FIC indexes between 0.125 and 0.375, and revealed indifferent effect on E0682. When MP-AF combined with SXT, it also exhibited synergistic activity against E0158, E0407, E0469, E0528, E0948 and E1359, showing FIC indexes between 0.25 and 0.5, and showed partial synergy against E0682. As MP-AF plus ciprofloxacin, it presented synergistic activity against E0528 and E0948, showing same FIC index of 0.375. When MP-AF combined with tetracycline, it displayed partial synergy against E0407, showing FIC index of 0.531, and additivity against E0469, E0528, E0682 and E1359, showing same FIC index of 1. However, MP-AF showed indifferent effects on all MDRAB when combined with ampicillin, cephalothin, gentamicin and neomycin with FIC indexes between 1.002 and 2.004.Table 5FIC indexes of combination studies between MP-AF and clinical used antibiotics against *A. baumannii* clinical isolates.AntibioticsFIC index (Conc.~MP-AF~/Conc.~antibiotic~), MP-AFE0158E0407E0469E0528E0682E0948E1359Ampicillin1.008(8/2)1.004(8/0.5)1.008(4/2)1.002(4/0.5)1.004(4/1)1.002(4/0.5)1.002(16/0.5)Cephalothin1.004(8/1)1.008(8/2)1.004(4/1)1.004(4/1)1.031(4/8)1.004(4/1)1.002(16/0.5)Ciprofloxacin1.125(8/32)1.016(8/1)1.002(4/0.5)**0.375(0.5/64)**1.016(4/4)**0.375(0.5/64)**1.002(16/0.5)Colistin**0.188(1/0.25)0.313(0.5/0.25)0.25(0.5/0.25)0.25(0.5/0.25)**2(4/2)**0.375(1/0.125)0.125(1/0.0625)**Gentamicin2.002(16/0.5)2.002(16/0.5)2.004(8/1)2.002(8/0.5)1.002(4/0.5)2.002(8/0.5)2.002(32/0.5)Neomycin2.002(16/0.5)2.002(16/0.5)2.002(8/0.5)2.004(8/1)2.002(8/0.5)2.002(8/0.5)1.004(16/1)SXT**0.5(2/64)0.5(2/64)0.25(0.5/32)0.25(0.5/32)**0.625(0.5/32)**0.375(0.5/64)0.5(4/64)**Tetracycline1.008 (8/2)0.531 (4/4)1 (2/64)1 (2/128)1 (2/128)1.004 (4/0.5)1 (8/128)[^5][^6][^7]

4. Discussion {#s0060}
=============

Gram-negative bacteria can resist the action of antibiotics by several mechanisms, *e.g.*, the resistance-nodulation-cell division (RND) efflux pump in *A. baumannii*. In this study, RND efflux pump genes *adeABC*, *adeIJK*, and *adeSR* were found in all *A. baumannii* clinical isolates. The AdeABC efflux pump, encoded by *adeABC* genes, could pump a broad spectrum of antibiotics, *e.g.*, aminoglycosides, cefotaxime, tetracyclines, erythromycin, chloramphenicol, trimethoprim, or fluoroquinolones to reduce antibiotics intake ([@b0055], [@b0140]). Similar to AdeABC, AdeIJK also offers resistance to β-lactams, chloramphenicol, tetracyclines, erythromycin, fluoroquinolones, fusidic acid, novobiocin, and trimethoprim ([@b0045]). As mentioned above, it could interpret that why *A. baumannii* isolates were resistant to antibiotics tested as shown in [Table 4](#t0020){ref-type="table"}. The *adeSR* genes, encoding sensor kinase and regulating the two-component system, were adjacent to *adeABC* genes, transcribed in the opposite direction, and located upstream from *adeA* ([@b0150], [@b0195]). The AdeSR two-component system could control the expression of AdeABC efflux pump by monitoring the environmental conditions ([@b0150]).

Our study demonstrated that MP-AF exhibited potent antimicrobial activity against the MDRAB and the reference strain, *A. baumannii* ATCC 15151, as compared with clinically used antibiotics. [@b0190] had evaluated the activity of 15 antimicrobial peptides against colistin-susceptible and colistin-resistant *A. baumannii*. It was noteworthy that mastoparan, isolated from the venom of *Vespula lewisii* ([@b0075]), showed better antimicrobial activity with lower MICs against colistin-susceptible and colistin-resistant *A. baumannii* than other antimicrobial peptides, *e.g.*, buforin I, histatin 5, magainin II and β-defensin, from other natural resources ([@b0190]).

MP-AF also showed effective antimicrobial activity with MICs ranging from 2 to 16 μg/ml against MDRAB isolates. Our previous study verified that MP-AF exhibited a broad-spectrum antimicrobial activity against both Gram-positive and -negative bacteria and displayed rapid bacterial killing activity against multidrug-resistant *E. coli* ([@b0130], [@b0125]). In addition, the cytotoxicity of MP-AF also has been evaluated by hemolytic activity assay and mast cell degranulation assay. MP-AF displayed negligible hemolytic activity on human erythrocytes, approximately 0.59% hemolysis, at the concentration of 32 μg/ml, and showed slight mast cell degranulation, 9.49%, at the concentration of 16 μg/ml ([@b0125]). It suggested that MP-AF could be non-toxic or displayed minor adverse effects on human body when exhibiting antimicrobial activity against MDRAB at effective dosages ranging from 2 to 16 μg/ml. Furthermore, when MP-AF interacted synergistically with antibiotics, it meant that the 4-fold or greater decrease in MIC of both antimicrobial agents in combination compared with antimicrobial agents tested individually. Even these combinations showed additive activity against MDRAB, it meant that the 2-fold decrease in MIC with both antimicrobial agents. Therefore, MP-AF combined with antibiotics could lower MP-AF dosage, reduce or abolish its mild adverse effects and improve its safety. It believed that MP-AF combined with antibiotics could be potential as a therapeutic alternative to combat MDRAB.

According to the results of analysis of RND efflux pump genes in MDRAB and *in vitro* activity of MP-AF against MRDAB, it found that RND efflux pumps had no effects on the antimicrobial efficacy of MP-AF against MDRAB isolates. MP-AF targeted membrane and caused severe permeabilization on *E. coli* BL21 at low concentration ([@b0125]). In addition, scanning electron microscopy (SEM) observation also verified that MP-AF acted on the surface of *E. coli* and caused irregular dents and perforations (Shyu et al., unpublished data) similar to mastoparan-M described by [@b0115]. As mentioned above, it suggested that antimicrobial potency of MP-AF could be unaffected by mechanism of antibiotic resistance in MDRAB. Thus, MP-AF has potential as alternative antimicrobial agent for humans against MDRAB infection in the clinical application.

Owing to lack of new antimicrobial agents and limited therapeutic options for *A. baumannii* infection, new uses for old drugs, *e.g.*, first-line antibiotic, SXT and highly adverse drug, colistin, has been proposed as a potential strategy to combat *A. baumannii* infection. However, the Taiwan Surveillance of Antimicrobial Resistance (TSAR) program revealed that *A. baumannii* displayed higher resistance rate to SXT exceeded 70% over the past ten years, 2000--2010 ([@b0100], [@b0105]). In the antimicrobial susceptibility testing, MDRAB isolates were almost resistant to these antibiotics tested, including ciprofloxacin and SXT. However, when ciprofloxacin or SXT combined with MP-AF, it exhibited synergistic activity against some MDRAB isolates. Interestingly, it also found that SXT combined with MP-AF was particularly effective against MDRAB isolates, being resistant to SXT. It suggested that with the aid of MP-AF, MDRAB isolates could be susceptible to SXT.

Mechanisms of antimicrobial resistance mainly included enzymatic degradation of antibiotics, alteration of antibiotic target proteins and decreased membrane permeability to antibiotics. SXT and ciprofloxacin resistance could be resulted from decreased membrane permeability. MP-AF has been verified that it could cause bacterial membrane permeabilization drastically at low concentration ([@b0125]). Thus, it suggested that MP-AF, the membrane-active peptide, could play an important role in synergistic combination against MDRAB. Our study speculated that MP-AF causes membrane permeabilization to allow ciprofloxacin or SXT, which act intracellularly, to facilitate cellular uptake and then against the bacteria. This process is similar to how other antimicrobial peptides acted synergistically with clinically used antibiotics ([@b0060], [@b0065], [@b0070], [@b0130]).

Colistin, used as a comparator, also showed potent activity against MDRAB isolates. In Taiwan, colistin is not a common treatment option for *A. baumannii*-infected patients and has been out of stock since 2009. Due to the adverse effect of colistin, nephrotoxicity, it could be explained why most *A. baumannii* isolates were susceptible to colistin. Owing to nephrotoxicity, treatment of *A. baumannii* infection by colistin should be recommended by medical advice. MP-AF in combination with colistin presented potent synergistic activity against MDRAB isolates. In addition, MP-AF/colistin combination could reduce at least 4-fold dosages of MP-AF and colistin; hence, it decreased adverse effects of colistin and also increased its safety in treating *A. baumannii*-infected patients. Previous clinical experience revealed that excessive and inappropriate use of antibiotics could accelerate emergence of antibiotic-resistant clinical isolates. However, we pointed out the feasible strategy, compound medication composed of naturally derived cationic antimicrobial peptide and chemical compound. These synergistic combinations could lower effective antimicrobial dosage to minimize adverse effect of antibiotics. Owing to decrease of antimicrobial dosage, it could reduce the selective pressure on pathogens to retard the emergence of antibiotic resistance. Furthermore, it also could elongate lifespan of antibiotics and gain more time to develop the new class of antibiotics.

Bacteria containing antimicrobial resistance genes affected the efficiency of antimicrobial combination therapy ([@b0130]). To overcome this problem, it is crucial to develop accurate and rapid diagnosis based on genetic analyses to detect antimicrobial resistance genes in pathogenic bacteria. Precise diagnosis will help clinicians to choose the appropriate antimicrobial combination therapy to treat specific bacterial infections.

This study revealed that MP-AF produced better antimicrobial results against MDRAB than antibiotics. MP-AF also acted synergistically with certain antibiotics, such as ciprofloxacin, SXT or colistin. Synergistic antimicrobial combination exhibited greater antibacterial activity than that would be expected from each drug individually. These results show that MP-AF alone or combined with other antibiotics has the potential to develop as a promising candidate for *A. baumannii* infections.
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[^1]: +, detected; −, not detected.

[^2]: --, not detected.

[^3]: *Abbreviations:* AN, amikacin; GM, gentamicin; SAM, ampicillin/sulbactam; TZP, piperacillin/tazobactam; CAZ, ceftazidime; CTX, cefotaxime; CRO, ceftriaxone; FEP, cefepime; IPM, imipenem; CIP, ciprofloxacin; LVX, levofloxacin; SXT, trimethoprim/sulfamethoxazole; MI, minocycline; S, susceptible; I, intermediate; R, resistant.

[^4]: *Abbreviations:* MIC, minimal inhibitory concentration; MP-AF, mastoparan-AF; AMP, ampicillin; CF, cephalothin; CIP, ciprofloxacin; CL, colistin; GM, gentamicin; NEO, neomycin; SXT, trimethoprim/sulfamethoxazole; TET, tetracycline; TGC, tigecycline.

[^5]: *Abbreviations:* MP-AF, mastoparan-AF; SXT, trimethoprim/sulfamethoxazole.

[^6]: The concentrations of MP-AF dilutions used were from 64 to 0.5 μg/ml, colistin were from 32 to 0.0625 μg/ml and those for seven antibiotics were from 256 to 0.5 μg/ml.

[^7]: The FIC indexes were defined as follows: FIC ⩽ 0.5, synergy (bolded); 0.5 \< FIC \< 1, partial synergy; FIC = 1, additivity; 1 \< FIC \< 4, indifference; FIC ⩾ 4.0, antagonism ([@b0050]).
